These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Dosing time and sex-related differences in the pharmacokinetics of cefodizime and in the circadian cortisol rhythm. Jonkman JH; Reinberg A; Oosterhuis B; de Noord OE; Kerkhof FA; Motohashi Y; Levi F; Dammacco F; Carandente F Chronobiologia; 1988; 15(1-2):89-102. PubMed ID: 3416675 [TBL] [Abstract][Full Text] [Related]
23. The clinical pharmacokinetics of levofloxacin. Fish DN; Chow AT Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926 [TBL] [Abstract][Full Text] [Related]
24. Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use. Kearns GL; Young RA Clin Pharmacokinet; 1994 Mar; 26(3):169-89. PubMed ID: 8194281 [TBL] [Abstract][Full Text] [Related]
25. Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Korting HC; Schäfer-Korting M; Maass L; Klesel N; Mutschler E Antimicrob Agents Chemother; 1987 Nov; 31(11):1822-5. PubMed ID: 3435129 [TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacokinetics of cimetidine. Somogyi A; Gugler R Clin Pharmacokinet; 1983; 8(6):463-95. PubMed ID: 6418428 [TBL] [Abstract][Full Text] [Related]
27. NONMEM analysis in determining the tri-exponential disposition of cefotaxime: a method of evaluating serum and urinary phase I data. Weber W; Harnisch L; Zimmer M; Rokitta C; Mendes P Int J Clin Pharmacol Ther; 1995 Oct; 33(10):560-4. PubMed ID: 8574507 [TBL] [Abstract][Full Text] [Related]
28. Cefodizime in skin suction blister fluid and serum following a single intravenous or intramuscular dose in adult patients. Mazzei T; Novelli A; Esposito S; Fallani S; Noviello S; Cassetta MI; Conti S; Periti P J Chemother; 2000 Aug; 12(4):306-13. PubMed ID: 10949980 [TBL] [Abstract][Full Text] [Related]
29. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Säwe J Clin Pharmacokinet; 1986; 11(2):87-106. PubMed ID: 3514045 [TBL] [Abstract][Full Text] [Related]
30. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692 [TBL] [Abstract][Full Text] [Related]
31. Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. Matsushita H; Suzuki H; Sugiyama Y; Sawada Y; Iga T; Hanano M; Kawaguchi Y J Pharmacobiodyn; 1990 Oct; 13(10):602-11. PubMed ID: 2095400 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of cefixime in the young and elderly. Faulkner RD; Bohaychuk W; Lanc RA; Haynes JD; Desjardins RE; Yacobi A; Silber BM J Antimicrob Chemother; 1988 Jun; 21(6):787-94. PubMed ID: 3410802 [TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417 [TBL] [Abstract][Full Text] [Related]